Related Experiment Videos
[Response prediction--early response evaluation. Consequences for surgical oncology]
1Chirurgische Klinik, Klinikum rechts der Isar, Technische Universität, Ismaninger Strasse 22, 81675, München, Deutschland. siewert@chir.med.tu-muenchen.de
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|November 23, 2006
Summary
Predicting patient response to perioperative chemotherapy or chemoradiation is challenging. Metabolic and molecular imaging using positron emission tomography (PET) offers early assessment of treatment effectiveness for many tumors.
Area of Science:
- Oncology
- Medical Imaging
- Molecular Biology
Context:
- Perioperative chemotherapy and chemoradiation are standard treatments for many solid tumors.
- Predicting treatment response using molecular markers remains difficult.
- Early assessment of treatment response is crucial for optimizing patient management.
Purpose:
- To review current knowledge on predicting and evaluating treatment response in perioperative cancer therapy.
- To highlight the role of metabolic and molecular imaging, specifically positron emission tomography (PET).
- To discuss the implications for clinical practice and future research.
Summary:
- Molecular marker analysis has limited ability to predict response to perioperative chemotherapy or chemoradiation.
- Positron emission tomography (PET) allows for early assessment of treatment response as early as 14 days after initiating chemotherapy for various tumors.
- A positive response to chemotherapy or chemoradiation significantly improves prognosis for patients with surgically resected tumors.
Impact:
- Early response evaluation using PET can guide treatment decisions, surgical indications, and the extent of surgery.
- This approach may lead to more personalized perioperative treatment strategies.
- Findings can inform the design of future clinical trials investigating novel predictive and response-monitoring tools.
